Ponvory

ponesimod · Laboratoires Juvisé Pharmaceuticals
AUTHORISED IN THE EU

What Ponvory is used for

Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Ponvory
Active substance
ponesimod
Disease area
Multiple Sclerosis, Relapsing-Remitting
Medicine group
Immunosuppressants
ATC code
L04AE04
Marketing authorisation holder
Laboratoires Juvisé Pharmaceuticals
Authorised in the EU since
2021

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Ponvory used for?

Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

What is the active substance in Ponvory?

Ponvory contains ponesimod.

Who makes Ponvory?

The EU marketing authorisation holder is Laboratoires Juvisé Pharmaceuticals.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.